{"id":652278,"date":"2023-05-22T09:20:02","date_gmt":"2023-05-22T09:20:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=652278"},"modified":"2023-05-22T09:20:02","modified_gmt":"2023-05-22T09:20:02","slug":"pheochromocytoma-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-study-period-20192032key-companies-molecular-insight-pharmaceuticals-pfizer-merck-pharmaceuticals-ge-healthca","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/pheochromocytoma-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-study-period-20192032key-companies-molecular-insight-pharmaceuticals-pfizer-merck-pharmaceuticals-ge-healthca_652278.html","title":{"rendered":"Pheochromocytoma Market is Expected to Expand at a Healthy Growth Rate During the Study Period (2019-2032)|Key Companies – Molecular Insight Pharmaceuticals, Pfizer, Merck Pharmaceuticals, GE Healthca"},"content":{"rendered":"
\n
\"Pheochromocytoma<\/a><\/div>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Pheochromocytoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Pheochromocytoma, historical and forecasted epidemiology as well as the Pheochromocytoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/div>\n

DelveInsight’s “Pheochromocytoma Market Insights, Epidemiology, and Market Forecast-2032<\/a>“<\/strong> report delivers an in-depth understanding of the Pheochromocytoma Market  epidemiology insights, Pheochromocytoma market trends, therapies, and key companies working in the Pheochromocytoma Market in the 7MM.<\/p>\n

Pheochromocytoma  Overview<\/strong><\/p>\n

Pheochromocytoma is a rare tumor of the adrenal medulla composed of chromaffin cells, also known as pheochromocytes. When a tumor composed of the same cells as a pheochromocytoma develops outside the adrenal gland, it is referred to as a paraganglioma. These neuroendocrine tumors typically release massive amounts of catecholamines, metanephrines, or methoxetamine, which result in the most common symptoms, including hypertension (high blood pressure), tachycardia (fast heart rate), and diaphoresis (sweating).[<\/a> Rarely, some tumors (especially paragangliomas) may secrete little to no catecholamines, making diagnosis difficult. While tumors of the head and neck are parasympathetic, their sympathetic counterparts are predominantly located in the abdomen and pelvis, particularly concentrated at the organ of Zuckerkandl.<\/p>\n

\"\"<\/p>\n

Pheochromocytoma Epidemiology Insights<\/strong><\/p>\n

The overall incidence of pheochromocytoma or paraganglioma was 0.66 cases per 100 000 people per year. The frequency of pheochromocytoma and paraganglioma increased with age and was highest in individuals aged 60–79 years (8.85 and 14.68 cases per 100 000 people per year for males and females, <\/p>\n

Click here to learn more about the Pheochromocytoma Market Landscape<\/a><\/strong><\/p>\n

The Report Covers the Pheochromocytoma Epidemiology Segmented by:<\/strong><\/p>\n